EXTON, Pa., Sept. 6, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission has granted a Centralized Pediatric Use Marketing Authorization (PUMA) for ...

Clinicians and carers of children and adolescents suffering from prolonged, acute, convulsive seizures now have access to Buccolam® (midazolam oromucosal solution), a newly approved rescue medication ...

Midazolam (BUCCOLAM®) is recommended as an option for use within NHS Wales for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to ...

"Buccolam, as a licensed preparation of buccal midazolam for emergency treatment of prolonged seizures, is a welcome additional option for care of children with epilepsy," commented Dr Bryan Lynch, ...

Buccolam is oral midazolam provided in a pre-measured, age-specific dose formulation for convenient buccal (i.e. via the cavity between the cheek and gum line) delivery. Buccal midazolam has been ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the CNS, announces the acquisition of the prescription brand Buccolam (oromucosal midazolam) from Takeda ...

DÜSSELDORF, Germany and BARCELONA, Spain, Sept. 14, 2020 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS ...

MONTREAL, Aug. 4, 2025 /CNW/ - Pendopharm, a division of Pharmascience Inc., is pleased to announce that it has entered into an exclusive distribution agreement with Neuraxpharm Group (Neuraxpharm), a ...

Acerca de Buccolam (R) (Midazolam, Solución bucal) Buccolam es midazolam oral que se presenta en una formulación de dosis individual para la administración bucal. Se presenta en una jeringa precargada ...

Wie ViroPharma Incorporated (Nasdaq: VPHM) heute bekannt gab, hat die Europäische Kommission Buccolam® (Midazolam, Lösung zur Anwendung in der Mundhöhle) eine zentralisierte Zulassung für die ...